Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

4 treatments under study, led by Patient Will Be Reversed With Sugammadex 4mgkg Iv

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

1Total
Phase 2/3 (1)

Trial Status

Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (1)

Showing 1 of 1 trials
Showing all 1 trials

Research Network

Common Treatments

  • Patient Will Be Reversed With Sugammadex 4mgkg Iv1
  • Standard Process1
  • Patients Will Be Inducted In The Induction Room1
  • Redesigned Process1

Active Sponsors

  • American University of Beirut Medical Center1
  • Merck Sharp & Dohme LLC1

Top Investigators

Related Conditions

  • Nonoperative Time1

Activity Timeline